Clinical Microbiology Laboratory, Infectious Diseases Department, Instituto Nacional de Ciencias Médica y Nutrición Salvador Zubirán, Mexico City, Mexico.
Division of Infectious Diseases, University of Texas Health Medical School, Houston, Texas.
Semin Respir Crit Care Med. 2020 Feb;41(1):3-12. doi: 10.1055/s-0040-1701215. Epub 2020 Jan 30.
Invasive candidiasis (IC) is the most frequent health care associated invasive fungal infection. It is also associated with high morbidity, mortality, and cost. The most frequent etiologic agent is , but non-albicans species are increasing and associated with reduced antifungal susceptibility and outbreaks. is an emerging multidrug-resistant species recently described. IC presents as a spectrum of disease, going from fungemia to deep-seated candidiasis, and to septic shock with multiorgan failure. Diagnosis of IC is challenging. Several biomarkers and molecular methods are available for improving diagnosis. Early initial treatment with echinocandins is the treatment of choice. Step-down therapy when antifungal susceptibility is available is possible. Several new antifungal agents for the treatment of IC are in clinical development.
侵袭性念珠菌病（IC）是最常见的与医疗保健相关的侵袭性真菌感染。它还与高发病率、死亡率和成本有关。最常见的病原体是 ，但非白念珠菌物种正在增加，并与抗真菌药物敏感性降低和爆发有关。 是最近描述的一种新兴的多药耐药物种。IC 表现为疾病谱，从菌血症到深部念珠菌病，再到感染性休克伴多器官衰竭。IC 的诊断具有挑战性。有几种生物标志物和分子方法可用于改善诊断。早期初始治疗使用棘白菌素类药物是首选治疗方法。当有抗真菌药物敏感性时，可以进行降阶梯治疗。有几种用于治疗 IC 的新型抗真菌药物正在临床开发中。
